TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27725885

Group type: EXPERIMENTAL
Intervention: Nutrition claims (healthy, diet, hedonic)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 352
Study: 25338995

Group type: EXPERIMENTAL
Intervention: Qigong intervention (8-week duration)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo (aerobic)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study: 22461242

Group type: EXPERIMENTAL
Intervention: Bacterial lipopolysaccharide (LPS; 0.4 ng/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study: 20578383

Group type: EXPERIMENTAL
Intervention: Continuous electroacupuncture at Neiguan (PC 6)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 56
Study: 18536865

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 microg/mm²)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 108
Study: 16835738

Group type: EXPERIMENTAL
Intervention: Nerve root infiltration guided by a nerve stimulator (n = 57)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nerve root infiltration without nerve stimulator (n = 39)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nerve root infiltration (overall)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nerve root infiltration with nerve stimulator
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nerve root infiltration guided by a nerve stimulator
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nerve root infiltration
Number of subjects: 96
Study: 12789172

Group type: EXPERIMENTAL
Intervention: Azelaic acid (15%) gel
Number of subjects: 664

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 664
Study: 11390165

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9136139

Group type: EXPERIMENTAL
Intervention: Audiocassette tape
Number of subjects: 86

Group type: COMPARATOR
Intervention: Verbal and written instruction combined with biofeedback
Number of subjects: 86
Study: 7942260

Group type: EXPERIMENTAL
Intervention: Fincoid-350 Short
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fincoid-350 Standard
Number of subjects: 0
Study: 2884152

Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg once daily
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2266679

Group type: COMPARATOR
Intervention: Aluminum hydroxide gel (Al[OH]3) (5 ml) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Al[OH]3 (5 ml) plus calcium acetate (Ca acetate) (1330 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Al[OH]3 (5 ml) plus calcium citrate (Ca citr) (950 mg)
Number of subjects: 10
Study: 961459

Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (previous neuroleptics)
Number of subjects: 0
Study: 31604139

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme
Number of subjects: 15856

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme for lower-risk patients
Number of subjects: 15856

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme for higher-risk patients
Number of subjects: 15856
Study: 26556778

Group type: EXPERIMENTAL
Intervention: Intervention group (completed EORTC QLQ-C30 and LC13 with feedback)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Attention group (completed questionnaire at baseline without feedback)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (did not complete the questionnaire)
Number of subjects: 138
Study: 26452399

Group type: EXPERIMENTAL
Intervention: RPE-13
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RPE-15
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RPE-17
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RPE-19
Number of subjects: 52
Study: 24274323

Group type: EXPERIMENTAL
Intervention: High-fiber snacks (10-12 g dietary fiber per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual snacks
Number of subjects: 81
Study: 21262918

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) 15 g/day for 4 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (non-prebiotic) for 4 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (non-prebiotic)
Number of subjects: 103
Study: 19136677

Group type: EXPERIMENTAL
Intervention: Health education intervention including physical activity, advice on healthy food intake, and social awareness activities for 15 months.
Number of subjects: 839

Group type: COMPARATOR
Intervention: Control group (no health education intervention).
Number of subjects: 839
Study: 17439761

Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiation (PMRT)
Number of subjects: 0
Study: 15338493

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral oriented self-management training with spouse participation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (only the patient participated)
Number of subjects: 59
Study: 11433992

Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program (Kehlet's method)
Number of subjects: 22
Study: 9738607

Group type: EXPERIMENTAL
Intervention: Generalist with cardiologist consultation
Number of subjects: 1716

Group type: EXPERIMENTAL
Intervention: Cardiologist alone
Number of subjects: 1716

Group type: COMPARATOR
Intervention: Generalist alone
Number of subjects: 1716
Study: 7816008

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (IVC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral calcitriol (ORC)
Number of subjects: 10
Study: 3281679

Group type: EXPERIMENTAL
Intervention: Acipimox (400 mg t.i.d. for type II patients, 250 mg t.i.d. for type IV patients)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Acipimox (400 mg t.i.d. for type II patients)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Acipimox (after 16-week follow-up)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (after 16-week follow-up)
Number of subjects: 130
Study: 31141553

Group type: EXPERIMENTAL
Intervention: Individuals with at least two symptoms of iNPH (n = 117)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Individuals aged 80 years and older
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Individuals aged 65-79 years
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Diagnosis according to Japanese guidelines
Number of subjects: 673
Study: 29028517

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy Volunteers
Number of subjects: 60
Study: 25413485

Group type: EXPERIMENTAL
Intervention: Scalp nerve blocks
Number of subjects: 32

Group type: COMPARATOR
Intervention: IV analgesia (piritramide 7.5 mg IV, plus oral metamizole)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cold-air analgesia
Number of subjects: 32
Study: 22076808

Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) rTMS for 20 min on the left dorsolateral prefrontal cortex
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 11
Study: 22111896

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib with progressive resistance training (PRT) and essential amino acids high in leucine.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib.
Number of subjects: 21
Study: 18579384

Group type: EXPERIMENTAL
Intervention: Physilog measurements on tar surface
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Physilog measurements on grass surface
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Physilog measurements on stones surface
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inter-visit ICC for all surfaces
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coefficient of variation (CV) for gait parameters
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bland and Altman Plots, SEM and SDC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall conclusion on Physilog
Number of subjects: 16
Study: 16841563

Group type: EXPERIMENTAL
Intervention: Aripiprazole (10-15 mg/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Haloperidol (9-15 mg/day)
Number of subjects: 103
Study: 12581571

Group type: EXPERIMENTAL
Intervention: GI ‐‐> VC regimen (gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m² followed by vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: VC ‐‐> GI regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m² followed by gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m²)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: VC regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: GC regimen (gemcitabine 1400 mg/m² + cisplatin 100 mg/m²)
Number of subjects: 400

Group type: COMPARATOR
Intervention: VC regimen
Number of subjects: 400

Group type: COMPARATOR
Intervention: GI ‐‐> VC regimen
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: VC and GC regimens
Number of subjects: 400
Study: 11127169

Group type: EXPERIMENTAL
Intervention: Lower gastrointestinal symptoms reported by participants during semi-structured physician interviews.
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Consultation behaviour regarding lower gastrointestinal symptoms.
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Consultation behaviour for significant new onset symptoms (rectal bleeding, abdominal pain, change in bowel habit).
Number of subjects: 745
Study: 8737130

Group type: EXPERIMENTAL
Intervention: sparfloxacin 200 mg once daily for 5 days following a loading dose of 400 mg on day 1
Number of subjects: 382

Group type: COMPARATOR
Intervention: cefuroxime axetil 250 mg twice daily for 8 days
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: sparfloxacin
Number of subjects: 382

Group type: COMPARATOR
Intervention: cefuroxime axetil
Number of subjects: 382
Study: 1317697

Group type: EXPERIMENTAL
Intervention: preoperative etoposide‐platinum (EP) chemotherapy‐surgery‐postoperative EP
Number of subjects: 27

Group type: COMPARATOR
Intervention: surgery‐postoperative mediastinal irradiation (SRT)
Number of subjects: 27
Study: 4025120

Group type: EXPERIMENTAL
Intervention: ECG Minnesota Q-QS codes
Number of subjects: 692
Study: 30843462

Group type: EXPERIMENTAL
Intervention: Actigraph inclinometer (AGincl)
Number of subjects: 10
Study: 29632222

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cholesterol management
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Smoking screening and counseling
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Composite measure (ABCs targets)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Aspirin use (solo practices)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Composite measure (solo practices)
Number of subjects: 134
Study: 26443196

Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate 75 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Clopidogrel bisulfate 75 mg
Number of subjects: 121
Study: 24532997

Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23742030

Group type: EXPERIMENTAL
Intervention: 20 mg bilastine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 80 mg bilastine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg bilastine
Number of subjects: 20
Study: 20008947

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (high dose, 300 mg every 2 weeks)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (medium dose, 405 mg every 4 weeks)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (low dose, 150 mg every 2 weeks)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (very low dose, 45 mg every 4 weeks)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Oral olanzapine
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Olanzapine long-acting injection (all doses combined)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (high dose)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (medium dose)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (low dose)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (very low dose)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Olanzapine long-acting injection and oral olanzapine
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection
Number of subjects: 1065
Study: 18439689

Group type: EXPERIMENTAL
Intervention: Partial tonsillectomy (PT) with scalpel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Total classical tonsillectomy (TT)
Number of subjects: 96
Study: 16171488

Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction
Number of subjects: 140

Group type: COMPARATOR
Intervention: No suction
Number of subjects: 140
Study: 12902571

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.5% solution
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.15% cream
Number of subjects: 358

Group type: COMPARATOR
Intervention: Podophyllin
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin solution
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream
Number of subjects: 358
Study: 10343591

Group type: EXPERIMENTAL
Intervention: B-technique of Regnault
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Eren technique
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Frey technique
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Free nipple-areola graft
Number of subjects: 81
Study: 7594445

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 7
Study: 2117741

Group type: EXPERIMENTAL
Intervention: Continuous, 24-hour nasogastric alimentation (group 1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Overnight, 12-hour nasogastric infusions plus daytime oral feedings (group 2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral feedings alone (group 3)
Number of subjects: 19
Study: 7004250

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Morphine 7.5 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25
Study: 31942691

Group type: EXPERIMENTAL
Intervention: Contiguous state residents obtaining abortions in Georgia (n=4216)
Number of subjects: 752227

Group type: COMPARATOR
Intervention: Georgia residents obtaining abortions (n=29,264)
Number of subjects: 752227

Group type: EXPERIMENTAL
Intervention: Contiguous state residents
Number of subjects: 752227
Study: 29914012

Group type: EXPERIMENTAL
Intervention: Capsaicin application (CA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined remote ischemic conditioning with capsaicin application (Comb)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remote effect of capsaicin application (REC)
Number of subjects: 30
Study: 28630358

Group type: EXPERIMENTAL
Intervention: rVSVΔG‐ZEBOV‐GP vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study: 26372054

Group type: EXPERIMENTAL
Intervention: Emotional items (negatively valenced and arousing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral items
Number of subjects: 0
Study: 23190417

Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Left lateral position (LLP)
Number of subjects: 20
Study: 22007005

Group type: EXPERIMENTAL
Intervention: ADHD Internet portal intervention
Number of subjects: 49
Study: 18571875

Group type: EXPERIMENTAL
Intervention: Integrated CD and primary care during the index treatment episode
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Ongoing medical care (2-10 primary care visits) in the 5 years following intake
Number of subjects: 598

Group type: COMPARATOR
Intervention: Substance abuse-related medical conditions (SAMCs)
Number of subjects: 598
Study: 16781291

Group type: EXPERIMENTAL
Intervention: Famciclovir single-dose (1500 mg once)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Famciclovir single-day (750 mg twice a day for 1 day)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 12679675

Group type: EXPERIMENTAL
Intervention: Intraoperative hydrocortisone irrigation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no hydrocortisone irrigation)
Number of subjects: 20
Study: 10719296

Group type: EXPERIMENTAL
Intervention: Dust mite antigen (Dermatophagoides farinae)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli 026:B6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 1313746

Group type: EXPERIMENTAL
Intervention: 200 mg sumatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3893106

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) - prednisone
Number of subjects: 246

Group type: COMPARATOR
Intervention: Azathioprine (Aza) - prednisone - antilymphocyte globulin
Number of subjects: 246
Study: 31299013

Group type: EXPERIMENTAL
Intervention: Nonstudy oral PrEP use
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Oral PrEP users
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Continuation of oral PrEP after study completion
Number of subjects: 195
Study: 28350282

Group type: EXPERIMENTAL
Intervention: Mobile-based rehabilitation (m-Health system)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study: 27266340

Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation for 30 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation
Number of subjects: 36
Study: 24825486

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MPH-SR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 110
Study: 23043755

Group type: EXPERIMENTAL
Intervention: CoSeal® (sealant group)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sutures/staples (control group)
Number of subjects: 216
Study: 20008679

Group type: EXPERIMENTAL
Intervention: AATAAC‐2 assessment after viewing AAC videos
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Viewing AAC videos with different gender combinations and device types
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 3-way interaction of familiarity, gender, and type of device
Number of subjects: 330
Study: 18593766

Group type: EXPERIMENTAL
Intervention: Obese women with PCOS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Obese PCOS women
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Normal-weight women with PCOS
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Normal-weight PCOS and controls
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All groups during hyperinsulinemia
Number of subjects: 62
Study: 15911816

Group type: EXPERIMENTAL
Intervention: Paroxetine (SSRI) for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12240793

Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day for 4 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 240

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 240
Study: 10406816

Group type: EXPERIMENTAL
Intervention: Beta-blockade therapy
Number of subjects: 268
Study: 8884862

Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated circuit
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncoated standard circuit
Number of subjects: 40
Study: 1363731

Group type: EXPERIMENTAL
Intervention: ALO 2145 1%
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6339595

Group type: EXPERIMENTAL
Intervention: Dutimelan 8-15 regimen (DTM 8-15): 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., placebo at 8 P.M.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 P.M. (Rx 15-20).
Number of subjects: 8
Study: 31272868

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived MSCs combined with biphasic calcium phosphate
Number of subjects: 39
Study: 29862925

Group type: EXPERIMENTAL
Intervention: Psychodynamic online treatment
Number of subjects: 0
Study: 26800411

Group type: EXPERIMENTAL
Intervention: Tailored, nurse-delivered interventions (video and printed education) based on nurse's risk assessment and patient's perception of risk.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 91
Study: 24638270

Group type: EXPERIMENTAL
Intervention: Low dose-fractionation (LD) group, total doses of 55 Gy and 44 Gy in 22 fractions to PTV1 and PTV2, respectively.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High dose-fractionation (HD) group, total doses of 66 Gy and 55 Gy in 22 fractions to PTV1 and PTV2, respectively.
Number of subjects: 53
Study: 22055739

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0